In response to findings of a safety signal report that there is reasonable suspicion of a causal association between use of Increlex® and childhood neoplasia, including malignancy, changes have been made to the Prescribing Information (PI) and Patient Package Insert (PPI) of Increlex ® (Mecasermin, recombinant human insulin-like growth factor-1) manufactured by Ipsen pharmaceuticals.
